ArticleWorld journal of gastroenterology2021
Tailored eradication strategy
Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Empirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review.BMC infectious diseases · 2025Pooled it
- Guideline
- Pooled it
- 14-day Empirical Therapy Compared with 7-day Tailored Therapy forYonsei medical journal · 2026Trial
- Culture-based susceptibility-guided tailored versus empirical concomitant therapy as first-line Helicobacter pylori treatment: A randomized clinical trial.United European gastroenterology journal · 2024Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- A Nationwide Trend Analysis ofGut and liver · 2026Article
- Concomitant Versus Tailored Therapy Based on Antibiotic Resistance Profiles forJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Tailored therapy guided by genotypic resistance from gastric mucosa samples in the first-line treatment ofTherapeutic advances in gastroenterology · 2025Article
- Antimicrobial drug susceptibility testing for the management ofFrontiers in microbiology · 2025Review
- A Randomized, Prospective and Crossover Study, Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Population.Current therapeutic research, clinical and experimental · 2025Article
- Effectiveness of Susceptibility-Guided Therapy forInfection and drug resistance · 2025Article
- OptimizingGut and liver · 2023Review
- Antibiotic Resistance andThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Antibiotic Resistance, Susceptibility Testing and Stewardship inInternational journal of molecular sciences · 2023Review
- EmpiricalTherapeutic advances in gastroenterology · 2023Article
- Personalized Approach in Eradication ofAntibiotics (Basel, Switzerland) · 2022Review
- Empirical vs. Susceptibility-Guided Treatment ofFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibiotic resistance to
aimTo investigate the efficacy and safety profiles of TT for
methodsWe included patients (> 18 years) with an
resultsOf the 217 patients with a treatment naive
conclusionThe DPO-based TT regimen shows promising results in efficacy and safety profiles as a first-line
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.